Discussion
Neuroendocrine tumors (NETs), also known as Carcinoids, originally Karzinoide in 1907; (=Cancer like, not the preferred terminology anymore except in case of NETs of lung and thymus) are a heterogeneous group of relatively rare neoplasms arising from the diffuse neuroendocrine system. The clinical and pathologic features resemble both the organ of origin and neuroendocrine neoplasms. WHO (2010) has classified (Table 1 ) NETs based on site of origin, clinical syndrome and differentiation(1). They are classified as functional and non-functional, based on their secreted products. Nearly two-thirds are functional NETs and the classical example is carcinoid tumors. The other examples of functional NETs is insulinomas, gastrinomas, VIPomas (vasoactive intestinal peptide), glucagonomas and somatostatinomas (2). The classical midgut NETs was referred to as carcinoid which is now referred to as neuroendocrine tumors. The diagnosis is reliant on either positive histology, or elevated 24-hour urinary 5-HIAA levels. The latter test has a sensitivity of 75% and a specificity of up to 100%, provided that the use of certain drugs and foods are excluded. Most NETs express synaptophysin (a synaptic vesicle glycoprotein present in neuroendocrine cells) and chromogranin-A by immune-histochemistry. Chromogranin-A by contrast, is a nonspecific marker, and is often raised in patients with a carcinoid tumor. Depending on the cut-off values and assays used, its sensitivity and specificity are 75% and 84%, respectively.(3,4).
NETs can arise anywhere in the body but the most common site of origin is the gastrointestinal tract (GIT-67.5%), since it is the largest reservoir of neuroendocrine cells followed by the bronchopulmonary system (25.3%). In the GIT most of them occur in the small intestine (41.8%), rectum(27.4%), and stomach(8.7%). These tumors have a female preponderance and most frequently seen in fifth to seventh decades. NETs may secrete as many as forty secretory products (vasoactive substances), the most prominent being 5-hydroxytryptamine (5-HT=serotonin). These tumor products are usually inactivated by the liver but when the production exceeds the capacity for degradation, the classical carcinoid syndrome (CS) ensues (10-15% of all carcinoids). The triad of CS is cutaneous flushing, bronchospasm with wheezing and. It is a well known fact that only one third of carcinoids present with the typical triad (5). Most patients with NETs have metastatic disease at diagnosis, with regional or distant metastasis observed in 50% of patients (6) . Duodenal tumors <1cm rarely metastasize, whereas 33% of those >2 cm do. Liver metastases are usually solid and vascular which on CT and magnetic resonance (MR) scans are accentuated with contrast. Primarily cystic appearance is exceedingly rare in untreated duodenal NETs and all the reports are in association with ileal NETs.(7) Cystic changes due to central tumor necrosis, are described in hepatic metastases after chemotherapeutic treatment.
Carcinoid heart disease (CHD-Hedinger syndrome) is a rare and unique manifestation seen in up to 60% of patients with NETs, typically inducing abnormalities of the right side of the heart. CHD is associated most frequently with NETs originating in the small bowel (72%). A slight male preponderance(60%) has been reported, with a mean age at diagnosis of 56-63 years. (8) Our patient being a male patient, in his late sixties presented with features of severe anemia (hb-4.4gm%), bilateral pitting pedal edema, severe TR and weight loss. The TR was not explained by his co-morbidities and was presumed to be related to the carcinoid. It could have been a mild TR secondary to carcinoid accentuated by the severe anemia. A urinary HIAA level was not done as the invasive workup confirmed the diagnoses in a very short time.
In conclusion, carcinoid known for its varied sites of origin can be confusing, but a high index of suspicion with an early HPE helps in confirming the diagnoses and early plan of care. Based on this report we can safely conclude that carcinoid should be considered in differential diagnoses of all anemias. 
